Please login to the form below
Cell Therapeutics Inc
This page shows the latest Cell Therapeutics Inc news and features for those working in and with pharma, biotech and healthcare.
CTI launches cancer drug Pixuvri in UK
Cell Therapeutics Inc (CTI) has launched its cancer treatment Pixuvri in the UK. ... Pixuvri (pixantrone) becomes the first drug available in the UK as a monotherapy treatment option for adults with multiply relapsed or refractory aggressive B-cell
Latest news
-
Baxter licenses cancer drug from CTI in $172m deal
Cell Therapeutics Inc (CTI) has met its objective of finding a commercial partner for cancer candidate pacritinib by the end of the year, licensing rights to the drug to Baxter for
-
Gilead expands in cancer with $510m YM BioSciences deal
Aside from Jakafi, other JAK inhibitors being developed for myelofibrosis include Sanofi's selective JAK2 inhibitor SAR302503 - phase II data for which were presented at ASH - and Cell Therapeutics Inc's
-
ASH meeting hears of progress with myelofibrosis drugs
The absentee at ASH this year among the myelofibrosis candidates was Cell Therapeutics Inc's recently-licensed pacritinib, which like Sanofi's drug is a selective JAK2 inhibitor and has also
-
Cell Therapeutics pulls Pixuvri filing for non-Hodgkin's lymphoma
Cell Therapeutics pulls Pixuvri filing for non-Hodgkin's lymphoma. Additional time needed to prepare for FDA review. ... Cell Therapeutics Inc (CTI) has withdrawn its marketing application of non-Hodgkin's lymphoma (NHL) drug candidate Pixuri (pixantrone)
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Deal Watch February 2016
licence, collaboration expanded. 830. Adaptimmune Therapeutics/ GSK. TCR engineered T-cell therapies inc affinity enhanced T-cell immunotherapy targeting NY-ESO-1 (p1/2); 4 other progs and combination studies. ... acquisition - product. 190. Annapurna
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
- Account Manager – Med Comms – London
-
Salary TBC
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- Editor – Medical Education Agency – Bucks
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Medical Writer
-
Great salary and bebefits
-
Scientific Director
-
Great salary and bebefits
-
Senior Programme Executive
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Account Manager / Account Director
-
Great salary and bebefits
Subscribe to our email news alerts
PMHub
M3 (EU)
M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...
Latest intelligence
- No incentive for a cure
- The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
- Why heading online for scientific meetings can yield greater HCP engagement
- Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
- The threat of antimicrobial resistance
- Why this issue is such a fundamental challenge...
Quick links
Infographics
